Tommy Love, MD
Internal Medicine · Little Rock, ARNPI 1689681355
Payments from drug & device makers
Across 217 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$742
- GSK$710
- Novartis$410
- Johnson & Johnson$271
- Astellas Pharma US Inc$232
- Boehringer Ingelheim$217
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,836100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $742 |
| GSK | 32 | $710 |
| Novartis | 26 | $410 |
| Johnson & Johnson | 18 | $271 |
| Astellas Pharma US Inc | 17 | $232 |
| Boehringer Ingelheim | 11 | $217 |
| Pfizer | 15 | $194 |
| Sanofi-aventis U.S. LLC | 12 | $148 |
| Novo Nordisk | 9 | $126 |
| Amarin Pharma, Inc. | 7 | $118 |
| Abbott | 4 | $104 |
| Abiomed | 1 | $76 |
| Biogen | 4 | $68 |
| Bayer | 3 | $67 |
| Lilly USA, LLC | 3 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Baxter Healthcare | 1 | $57 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Merck | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$116
- FARXIGA$105
- TRELEGY ELLIPTA$105
How this compares
$3,842 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 190 | $200,619 |
| OzempicSemaglutide | 162 | $181,057 |
| EliquisApixaban | 147 | $129,741 |
| FarxigaDapagliflozin Propanediol | 131 | $108,293 |
| MounjaroTirzepatide | 78 | $96,332 |
| JanuviaSitagliptin Phosphate | 71 | $62,522 |
| TrulicityDulaglutide | 60 | $61,902 |
| XareltoRivaroxaban | 66 | $54,906 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $53,348 |
| EntrestoSacubitril/Valsartan | 48 | $45,535 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $42,644 |
| LinzessLinaclotide | 38 | $32,786 |
| MyrbetriqMirabegron | 43 | $27,516 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $24,028 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $21,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $217 | $211,636202 claims |
| Novo NordiskOzempic, Rybelsus | $126 | $195,682176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $60 | $158,234138 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $742 | $134,333211 claims |
| PfizerEliquis | $194 | $129,741147 claims |
| MerckJanuvia | $33 | $62,52271 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $271 | $62,06478 claims |
| GSKTrelegy Ellipta | $710 | $53,34866 claims |
| NovartisEntresto | $410 | $45,53548 claims |
| AbbVieLinzess | $12 | $32,78638 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $27,51643 claims |
| BayerKerendia | $67 | $14,00524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Little Rock
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- Alexander KaczenskiLittle Rock$305K
- Manisha SinghLittle Rock$71K
- Srikanth VallurupalliLittle Rock$34K
- Aaron StrobelLittle Rock$32K
- Jeremy DavisLittle Rock$17K
- Ritesh RampureLittle Rock$13K
- Milton RoachLittle Rock$12K
- Michael CloudLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.